Tag: heart failure

Bariatric Surgery’s Cardiovascular Benefit Extends to 7 Years

Patients with obesity who had bariatric surgery had a lower risk of having a major adverse cardiovascular event (MACE) or dying from all causes during...

More Evidence Links COVID Vaccines to Rare Myocarditis in Youth

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Swelling of the heart appears to be a very rare side...

Evidence Builds for iPhone 12 Interference With Cardiac Devices

Further evidence that powerful magnets in some Apple iPhones can interfere with cardiac implantable electronic devices (CIEDs) comes from a small study that also suggests...

Dispatch System Boosts Bystander CPR in Those With Limited English

The improved Los Angeles medical dispatch system prompted more callers with limited English proficiency to initiate telecommunicator-assisted cardiopulmonary resuscitation (T-CPR), compared with the previous system,...

Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

Of patients with symptomatic, obstructive hypertrophic cardiomyopathy treated with the investigational oral agent mavacamten, more than twice as many, compared with placebo, had a very...

PASCAL Mitral Valve Repair Shines at 2 Years in CLASP

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm,...

Sotagliflozin’s HFpEF Benefit Confirmed by New Analyses

It’s now official: The investigational sodium-glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin is the first agent clearly shown in a prespecified analysis of randomized trials to improve...

Underlying Heart Rhythm, Not ICD Shocks, Drives Mortality

Combined data from five implantable cardioverter-defibrillator (ICD) trials suggest that it is the underlying arrhythmic disorder, rather than the ICD therapy itself, that affects mortality...

Ultrasound Renal Denervation Drops BP in Patients on Triple Therapy

Renal denervation’s comeback as a potential treatment for patients with drug-resistant hypertension rolls on. Renal denervation with ultrasound energy produced a significant, median 4.5–mm Hg...

Torsemide Over Furosemide as First-Line Loop Diuretic for HF

Dr Anthony C. Breu When starting a new loop diuretic for a patient with heart failure, strongly consider torsemide over furosemide, Anthony C. Breu, MD, advised...

Infective Endocarditis With Stroke Post-TAVR: ‘Dismal’ Prognosis

Patients who suffer a stroke during hospitalization for infective endocarditis (IE) after transcatheter aortic valve replacement (TAVR) have a dismal prognosis, with more than half...

Heart Retrieval Technique May Boost Organs for Transplant by 20%

In a small observational study that tested normothermic regional perfusion (NRP) for donation after cardiac death (DCD), posttransplant cardiac function was “excellent” in 8 of...

BP Lowering Useful in CV Risk Management Even at Normal Levels

Lowering blood pressure with antihypertensive medication protects against future cardiovascular (CV) events even in people with normal or only mildly elevated blood pressure, a large...

FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease

The US Food and Drug Administration (FDA) has approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk for kidney function decline, kidney failure, cardiovascular death, and...

Trade-offs Between S-ICD, Transvenous ICDs Shown in EFFORTLESS

One of the largest and longest follow-ups of patients implanted with the subcutaneous-lead implantable cardioverter defibrillator (S-ICD), now marketed as the EMBLEM S-ICD (Boston Scientific),...

New AHA Guidance on Obesity and Cardiovascular Risk

An updated American Heart Association scientific statement on the role of obesity in cardiovascular disease provides the first new guidance in 15 years, drawing on...

Post-COVID Cardiac Involvement Rare in College Athletes

Young athletes are unlikely to experience ongoing heart problems post–COVID-19 infection. In a multicenter study conducted during September-December 2020, only 0.7% of 3,018 collegiate athletes...

Black Patients With Sarcoidosis Have More Systemic, CV Disease

Black patients diagnosed by dermatologists with cutaneous sarcoidosis were significantly more likely to have unrecognized systemic organ involvement than were non-Black patients, according to a...

Arthritis Drug May Curb Myocardial Damage in Acute STEMI

Early use of tocilizumab (Actemra) does not reduce myocardial infarct size but modestly increases myocardial salvage in patients with acute ST-segment elevation myocardial infarction (STEMI),...

Riociguat an Option for Pulmonary Arterial Hypertension When PDE-5 Inhibitors Fail

NEW YORK (Reuters Health) – Patients with pulmonary arterial hypertension (PAH) at intermediate risk of death within a year may be switched from a phosphodiesterase-5...

Heart Failure Redefined With New Classifications, Staging

The terminology and classification scheme for heart failure (HF) is changing in ways that experts hope will directly impact patient outcomes. In a new consensus...

A Day in the Life of My Heart Failure

By Aimee Rodriguez Zepeda, as told to Danny Bonvissuto I didn’t have the typical feeling people describe, like trouble breathing. Instead, I was...

New Light Cast on Type-2 MI Aims to Sharpen Diagnosis, Therapy

The hospital and post-discharge course of patients diagnosed with type-2 myocardial infarction (MI), triggered when myocardial oxygen demand outstrips supply, differs in telling ways from...

FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF

The US Food and Drug Administration (FDA) has approved a groundbreaking expanded indication for sacubitril/valsartan (Entresto), making it the first drug in the United States...

Training Regimens Fall Short in Trial

Exercise promotes conditioning and boosts quality of life in patients with heart failure with preserved ejection fraction (HFpEF), so different training regimens have been proposed...